Miya ishemiyasi darajasini baholashda gemodializda 2-toifa qandli diabet bilan og'rigan bemorlarda WHOQOL-BREF so'rovnomasi va BNDF neyromarkerining ahamiyati

This study aims to evaluate the significance of the WHOQOL-BREF questionnaire, a tool for assessing quality of life, and the biomarker brain-derived neurotrophic factor (BDNF) in patients with type 2 diabetes mellitus (T2DM) complicated by chronic kidney disease (CKD) who are receiving hemodialysis. A total of 90 patients with T2DM and stage III chronic renal failure (CRF) undergoing programmed hemodialysis were examined between January 1, 2019, and December 31, 2020. These patients were divided into three groups based on the severity of chronic cerebral ischemia (CCI). The results showed that as the degree of CCI increased, serum levels of BDNF decreased significantly compared to the control group. Additionally, significant correlations were found between WHOQOL-BREF scores and various clinical, laboratory, and instrumental parameters, including the duration of the disease, fasting blood glucose, glycated hemoglobin levels, BDNF, and blood flow velocity in the carotid and vertebral arteries. The study highlights the importance of the WHOQOL-BREF questionnaire in assessing the quality of life in this patient population and identifies BDNF as a valuable marker for brain ischemia in T2DM patients undergoing hemodialysis.

Hali tarjima qilinmagan